125 related articles for article (PubMed ID: 38330766)
1. First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M; Froesch P; Gysel K; Rothschild SI; Addeo A; Ackermann CJ; Chiquet S; Schneider M; Ribi K; Maranta AF; Bastian S; von Moos R; Joerger M; Früh M;
Eur J Cancer; 2024 Mar; 200():113600. PubMed ID: 38330766
[TBL] [Abstract][Full Text] [Related]
2. SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M; Froesch P; Eboulet EI; Addeo A; Pless M; Rothschild SI; Janthur WD; Burmeister H; Friedlaender A; Schneider M; Metaxas Y; Joerger M; Wannesson L; Schwitter M; Baudoux N; Weindler S; Biaggi-Rudolf C; Früh M;
Cancer Immunol Immunother; 2021 May; 70(5):1255-1262. PubMed ID: 33130956
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
6. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
[TBL] [Abstract][Full Text] [Related]
8. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
9. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
[TBL] [Abstract][Full Text] [Related]
10. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
[TBL] [Abstract][Full Text] [Related]
12. Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
Reck M; Barlesi F; Yang JC; Westeel V; Felip E; Özgüroğlu M; Dols MC; Sullivan R; Kowalski DM; Andric Z; Lee DH; Sezer A; Hu P; Wang X; von Heydebreck A; Jacob N; Mehr KT; Park K
J Thorac Oncol; 2024 Feb; 19(2):297-313. PubMed ID: 37748693
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
14. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
Leighl NB; Laurie SA; Goss GD; Hughes BGM; Stockler M; Tsao MS; Hwang DM; Joubert P; Kulkarni S; Blais N; Joy AA; Mates M; Rana P; Yadav SK; Underhill C; Lee C; Bradbury PA; Hiltz A; Dancey J; Ding K; Vera-Badillo F;
J Thorac Oncol; 2022 Mar; 17(3):434-445. PubMed ID: 34800700
[TBL] [Abstract][Full Text] [Related]
15. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
[TBL] [Abstract][Full Text] [Related]
16. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
Cheng Y; Zhou Q; Han B; Fan Y; Shan L; Chang J; Sun S; Fang J; Chen Y; Sun J; Wu G; Mann H; Naicker K; Shire N; Mok T; de Castro G
Lung Cancer; 2023 Apr; 178():87-95. PubMed ID: 36806898
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
18. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
[TBL] [Abstract][Full Text] [Related]
19. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
